GAIN THERAPEUTICS INC. - COMMON STOCK

Gain Therapeutics to Participate in FORCE Family Office Event with Zacks Small-Cap Research

04 дек 2023 08:00:00 Источник Nasdaq GlobeNewswire

Gain Therapeutics Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis Model

01 дек 2023 08:00:00 Источник Nasdaq GlobeNewswire

Gain Therapeutics to Participate in AI Driven Drug Discovery Summit

29 ноя 2023 08:00:00 Источник Nasdaq GlobeNewswire

Gain Therapeutics Announces Closing of $10.1 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants, Including Full Exercise of Over-Allotment Option

24 ноя 2023 13:01:00 Источник Nasdaq GlobeNewswire

Gain Therapeutics Announces Pricing of $9.4 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants

21 ноя 2023 08:54:48 Источник Nasdaq GlobeNewswire

Gain Therapeutics Announces Proposed Public Offering

20 ноя 2023 16:03:43 Источник Nasdaq GlobeNewswire

Gain Therapeutics Announces Third Quarter 2023 Financial Results and Business Update

14 ноя 2023 07:00:00 Источник Nasdaq GlobeNewswire

Gain Therapeutics Announces Dosing of First Two Subjects in Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease

04 окт 2023 07:00:00 Источник Nasdaq GlobeNewswire

Gain Therapeutics to Participate at Cantor Fitzgerald Global Healthcare Conference 2023

25 сен 2023 16:05:00 Источник Nasdaq GlobeNewswire

Gain Therapeutics to Present at the Cambridge Healthtech Institute’s 2nd Annual Neurodegeneration Targets Conference

20 сен 2023 16:05:00 Источник Nasdaq GlobeNewswire

Gain Therapeutics Receives Approval to Commence Phase 1 Clinical Study of GT-02287 from the Human Research Ethics Committee (HREC) in Australia

12 сен 2023 09:25:00 Источник Nasdaq GlobeNewswire

Gain Therapeutics Presents New Preclinical Data Demonstrating a Reduction of Plasma Neurodegeneration Biomarker NfL after Administration of its Drug Candidate GT-02287 in GBA1 Parkinson’s Disease Model

28 авг 2023 07:00:00 Источник Nasdaq GlobeNewswire

Gain Therapeutics Announces Second Quarter 2023 Financial Results and Business Update

10 авг 2023 07:00:01 Источник Nasdaq GlobeNewswire

Gain Therapeutics Announces Acceptance of Late Breaking Abstract for Presentation at the International Congress of Parkinson’s Disease and Movement Disorders®

07 авг 2023 07:00:00 Источник Nasdaq GlobeNewswire

Gain Therapeutics to Participate in the 2023 BTIG Virtual Biotechnology Conference

31 июл 2023 08:00:00 Источник Nasdaq GlobeNewswire

Gain Therapeutics to Present at the Jefferies Healthcare Conference

01 июн 2023 08:00:01 Источник Nasdaq GlobeNewswire

Gain Therapeutics Reports First Quarter 2023 Financial Results and Business Update

12 май 2023 08:00:00 Источник Nasdaq GlobeNewswire

Gain Therapeutics Awarded CHF 2.5 million Innosuisse Grant to Advance Lead Program in GBA1 Parkinson’s Disease

03 май 2023 09:15:00 Источник Nasdaq GlobeNewswire

Gain Therapeutics Appoints C. Evan Ballantyne as Chief Financial Officer

12 апр 2023 16:30:00 Источник Nasdaq GlobeNewswire

Gain Therapeutics to Present Positive Preclinical Data on its GBA1 Program at the AD/PD 2023 Meeting

29 мар 2023 08:52:52 Источник Nasdaq GlobeNewswire